[8-K] ArriVent BioPharma, Inc. Reports Material Event

Rhea-AI Filing Summary

ArriVent BioPharma, Inc. disclosed that it issued a press release announcing its financial results for the second quarter ended June 30, 2025. The company furnished that press release as Exhibit 99.1 to this Form 8-K, and also included a Cover Page Interactive Data File as Exhibit 104. The filing states the press release and related information are being furnished and are not to be deemed "filed" under the Securities Exchange Act.

The Form 8-K itself does not include the financial figures or operating metrics; the substantive results are contained in the press release referenced as Exhibit 99.1.

Insights

Financial Analyst

TL;DR: Routine earnings disclosure furnished; no financial details contained in this 8-K, so immediate investor impact is limited.

The filing informs investors that ArriVent has publicly released its second-quarter results via a press release (Exhibit 99.1). Because the 8-K merely furnishes the press release rather than filing financial statements or detailed metrics within the form, there is no new quantitative information in this filing to assess trends in revenue, expenses, cash position, or guidance. The disclosure is standard practice to make quarterly results publicly available while clarifying that the exhibit is "furnished" and not "filed," which has legal significance for certain liabilities.

Corporate Governance Expert

TL;DR: Governance procedure followed appropriately; exhibit furnishing limits legal exposure but provides transparency on public release.

The 8-K documents a routine communication step: furnishing a press release and interactive data as exhibits. The signature by the CFO indicates proper authorization. The statement that the exhibit is "furnished" rather than "filed" is a common governance/legal position to limit Section 18 and Securities Act liabilities. There are no governance or disclosure irregularities evident from the text provided, but material assessment requires review of the actual press release (Exhibit 99.1) for substantive financial or operational developments.

0001868279false00018682792025-08-112025-08-11

​

​

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

FORM 8-K

​

CURRENT REPORT 

Pursuant to Section 13 or 15(d) 

of the Securities Exchange Act of 1934

​

Date of Report (Date of earliest event reported): August 11, 2025

​

ARRIVENT BIOPHARMA, INC.

(Exact name of registrant as specified in its charter)

​

Delaware		001-41929		86-3336099
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

​

​ ​
18 Campus Boulevard, Suite 100 Newtown Square, PA		19073
(Address of principal executive offices)		(zip code)

​

Registrant’s telephone number, including area code: (628) 277-4836

​

N/A 

(Former name or former address, if changed since last report.)

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

​

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

​

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

​

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

​

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

​

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		AVBP		The Nasdaq Stock Market LLC

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

​

Emerging Growth Company ☒

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

Item 2.02 Results of Operations and Financial Condition.

​

On August 11, 2025, ArriVent BioPharma, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 hereto.

​

The information contained in this Item 2.02 and in the press release furnished as Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended, or incorporated by reference in any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

​

​

Item 9.01 Financial Statements and Exhibits.

​

(d) Exhibits.

Exhibit No.		Description
99.1	​	Press Release dated August 11, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

​

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	ARRIVENT BIOPHARMA, INC.
	By:	/s/ Winston Kung
		Winston Kung
		Chief Financial Officer and Treasurer

​

Date: August 11, 2025

​

​

​